The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Research Report 2025
Synopsis
Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers include GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for NASH (Non-alcoholic Steatohepatitis) Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NASH (Non-alcoholic Steatohepatitis) Biomarkers.
Report Scope
The NASH (Non-alcoholic Steatohepatitis) Biomarkers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc
Segment by Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
Segment by Application
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of NASH (Non-alcoholic Steatohepatitis) Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers include GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for NASH (Non-alcoholic Steatohepatitis) Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NASH (Non-alcoholic Steatohepatitis) Biomarkers.
Report Scope
The NASH (Non-alcoholic Steatohepatitis) Biomarkers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc
Segment by Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
Segment by Application
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of NASH (Non-alcoholic Steatohepatitis) Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Overview
1.1 Product Overview and Scope of NASH (Non-alcoholic Steatohepatitis) Biomarkers
1.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Type
1.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Type (2024-2030)
1.2.2 Serum Biomarkers
1.2.3 Hepatic Fibrosis Biomarkers
1.2.4 Apoptosis Biomarkers
1.2.5 Oxidative Stress Biomarkers
1.2.6 Others
1.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Application
1.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value by Application: (2024-2030)
1.3.2 Pharma & CRO Industry
1.3.3 Hospitals
1.3.4 Diagnostic Labs
1.3.5 Academic Research Institutes
1.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Estimates and Forecasts
1.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2019-2030
1.4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2019-2030
1.4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competition by Manufacturers
2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturers (2019-2024)
2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Manufacturers (2019-2024)
2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Average Price by Manufacturers (2019-2024)
2.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Product Type & Application
2.7 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competitive Situation and Trends
2.7.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest NASH (Non-alcoholic Steatohepatitis) Biomarkers Players Market Share by Revenue
2.7.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Retrospective Market Scenario by Region
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region: 2019-2030
3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region: 2019-2024
3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region: 2025-2030
3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2019-2030
3.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2019-2024
3.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2025-2030
3.4 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country
3.4.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2030)
3.4.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country
3.5.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2030)
3.5.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country
3.6.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2030)
3.6.3 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country
3.7.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2030)
3.7.3 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country
3.8.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2030)
3.8.3 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2019-2030)
4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2019-2024)
4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2025-2030)
4.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2019-2030)
4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2019-2030)
4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2019-2024)
4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2025-2030)
4.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2019-2030)
4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2019-2030)
5 Segment by Application
5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2019-2030)
5.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2019-2024)
5.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2025-2030)
5.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2019-2030)
5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2019-2030)
5.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2019-2024)
5.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2025-2030)
5.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2019-2030)
5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GENFIT SA
6.1.1 GENFIT SA Corporation Information
6.1.2 GENFIT SA Description and Business Overview
6.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.1.5 GENFIT SA Recent Developments/Updates
6.2 Gilead Sciences, Inc. (GILD)
6.2.1 Gilead Sciences, Inc. (GILD) Corporation Information
6.2.2 Gilead Sciences, Inc. (GILD) Description and Business Overview
6.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.2.5 Gilead Sciences, Inc. (GILD) Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Corporation Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 Allergan Plc
6.6.1 Allergan Plc Corporation Information
6.6.2 Allergan Plc Description and Business Overview
6.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.6.5 Allergan Plc Recent Developments/Updates
6.7 Novo Nordisk A/S
6.6.1 Novo Nordisk A/S Corporation Information
6.6.2 Novo Nordisk A/S Description and Business Overview
6.6.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.7.5 Novo Nordisk A/S Recent Developments/Updates
6.8 Boehringer Ingelheim
6.8.1 Boehringer Ingelheim Corporation Information
6.8.2 Boehringer Ingelheim Description and Business Overview
6.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.8.5 Boehringer Ingelheim Recent Developments/Updates
6.9 Pfizer Inc
6.9.1 Pfizer Inc Corporation Information
6.9.2 Pfizer Inc Description and Business Overview
6.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio
6.9.5 Pfizer Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Chain Analysis
7.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Mode & Process
7.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales and Marketing
7.4.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Channels
7.4.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
7.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers
8 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Dynamics
8.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Trends
8.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
8.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges
8.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competitive Situation by Manufacturers in 2023
Table 4. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturers (2019-2024)
Table 6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market NASH (Non-alcoholic Steatohepatitis) Biomarkers Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Product Type & Application
Table 12. Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NASH (Non-alcoholic Steatohepatitis) Biomarkers as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2019-2024) & (K Units)
Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2019-2024)
Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2025-2030) & (K Units)
Table 20. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2025-2030)
Table 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2019-2024)
Table 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2025-2030)
Table 25. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2024) & (K Units)
Table 27. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2025-2030) & (K Units)
Table 28. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2024) & (K Units)
Table 32. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2025-2030) & (K Units)
Table 33. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2024) & (K Units)
Table 42. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2025-2030) & (K Units)
Table 43. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Type (2019-2024)
Table 51. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Type (2025-2030)
Table 52. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2019-2024)
Table 53. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2025-2030)
Table 54. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Type (2019-2024)
Table 55. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Type (2025-2030)
Table 56. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2019-2024)
Table 57. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2025-2030)
Table 58. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Type (2019-2024)
Table 59. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Type (2025-2030)
Table 60. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Application (2019-2024)
Table 61. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Application (2025-2030)
Table 62. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2019-2024)
Table 63. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2025-2030)
Table 64. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Application (2019-2024)
Table 65. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Application (2025-2030)
Table 66. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2019-2024)
Table 67. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2025-2030)
Table 68. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Application (2019-2024)
Table 69. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Application (2025-2030)
Table 70. GENFIT SA Corporation Information
Table 71. GENFIT SA Description and Business Overview
Table 72. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 74. GENFIT SA Recent Developments/Updates
Table 75. Gilead Sciences, Inc. (GILD) Corporation Information
Table 76. Gilead Sciences, Inc. (GILD) Description and Business Overview
Table 77. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 79. Gilead Sciences, Inc. (GILD) Recent Developments/Updates
Table 80. AstraZeneca Corporation Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. Novartis AG Corporation Information
Table 86. Novartis AG Description and Business Overview
Table 87. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 89. Novartis AG Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Corporation Information
Table 91. Bristol-Myers Squibb Company Description and Business Overview
Table 92. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
Table 95. Allergan Plc Corporation Information
Table 96. Allergan Plc Description and Business Overview
Table 97. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 99. Allergan Plc Recent Developments/Updates
Table 100. Novo Nordisk A/S Corporation Information
Table 101. Novo Nordisk A/S Description and Business Overview
Table 102. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 104. Novo Nordisk A/S Recent Developments/Updates
Table 105. Boehringer Ingelheim Corporation Information
Table 106. Boehringer Ingelheim Description and Business Overview
Table 107. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 109. Boehringer Ingelheim Recent Developments/Updates
Table 110. Pfizer Inc Corporation Information
Table 111. Pfizer Inc Description and Business Overview
Table 112. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
Table 114. Pfizer Inc Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List
Table 118. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers List
Table 119. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends
Table 120. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
Table 121. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges
Table 122. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Type in 2023 & 2030
Figure 4. Serum Biomarkers Product Picture
Figure 5. Hepatic Fibrosis Biomarkers Product Picture
Figure 6. Apoptosis Biomarkers Product Picture
Figure 7. Oxidative Stress Biomarkers Product Picture
Figure 8. Others Product Picture
Figure 9. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Application in 2023 & 2030
Figure 11. Pharma & CRO Industry
Figure 12. Hospitals
Figure 13. Diagnostic Labs
Figure 14. Academic Research Institutes
Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size (2019-2030) & (US$ Million)
Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (2019-2030) & (K Units)
Figure 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Average Price (USD/Unit) & (2019-2030)
Figure 19. NASH (Non-alcoholic Steatohepatitis) Biomarkers Report Years Considered
Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Manufacturers in 2023
Figure 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest NASH (Non-alcoholic Steatohepatitis) Biomarkers Players: Market Share by Revenue in 2023
Figure 23. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2019-2030)
Figure 26. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2019-2030)
Figure 27. U.S. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2019-2030)
Figure 30. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2019-2030)
Figure 31. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2019-2030)
Figure 38. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Taiwan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Indonesia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Thailand NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Malaysia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Philippines NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2019-2030)
Figure 49. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2019-2030)
Figure 50. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2019-2030)
Figure 55. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Type (2019-2030)
Figure 59. Global Revenue Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Type (2019-2030)
Figure 60. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Application (2019-2030)
Figure 62. Global Revenue Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Application (2019-2030)
Figure 63. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Application (2019-2030)
Figure 64. NASH (Non-alcoholic Steatohepatitis) Biomarkers Value Chain
Figure 65. NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
